Signal Genetics (SGNL) Reports Q1 Loss of Per Share $0.26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Signal Genetics Highlights Recent Achievements and Reports First Quarter 2016 Financial Results
May 16, 2016 8:31 AM EDTCARLSBAD, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ: SGNL) (Signal or the Company), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today reported recent achievements and financial results for the first quarter ended March 31, 2016.
Recent Highlights
Record net revenue from clinical customers increased 244% in the first quarter of 2016 over first quarter of 2015Record number of tests billed for clinical customers was 93%... More